Oncology Phase 3 Deal Benchmarks — Ex-US

Understanding Oncology Deal Benchmarks at Phase 3

Phase 3 Oncology licensing deals in Ex-US territory command a median upfront payment of $324M, with values ranging from $212M at the low end to $460M for premium assets. These benchmarks reflect the risk-adjusted value of clinical-stage assets in the oncology therapeutic area, where development costs, competitive dynamics, and market potential all factor into deal pricing.

Total deal values — including milestones for development, regulatory, and commercial achievements — range from $1.1B to $1.8B, with a median of $1.4B. Royalty rates for oncology assets at this stage typically fall between 12.7% and 19.4% of net sales, reflecting the balance between licensor value contribution and licensee commercialization investment.

The Ex-US territory applies a 0.45x multiplier to base deal economics. This accounts for market size, regulatory complexity, pricing environment, and competitive landscape differences across geographies. Licensors negotiating ex-us rights should calibrate upfront expectations and milestone structures accordingly.